First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will look at how safe, tolerable and effective SD-809 ER is compared to placebo (inactive drug) in reducing chorea. First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have not taken tetrabenazine (Xenazine ®, Nitoman ®) in the past 6 months may be eligible. Participants will be involved in this trial for approximately 4 months.

The First-HD Trial is being conducted by the Huntington Study Group (HSG) under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University). Approximately 30 HSG research sites across the United States and Canada will enroll about 90 people with HD.

For: HD positive individuals who are experiencing symptoms of HD and have not taken Tetrabenazine in the past 6 months. Click here for detailed eligibility information and exclusion criteria.

FAQ from the Huntington’s Study Group

Eligibility and other trial information from

Huntington’s Study Group list of participating sites and contact people